Aprovix wins tender in Belgium

Qvintip was chosen by the Belgian authorities for a study later this fall with 12,000 women participating. Qvintip has now been selected in over twenty countries due to its ease of use and comfort. Qvintip is the choice of an overwhelming majority of women. For more info, please contact Lana Obolenskaja at lana@aprovix.com

New study verifies cost effectiveness for self-sampling.

Objective. This study aims to identify possible barriers to and facilitators of cervical cancer screening by (a) estimating time and travel costs and other direct non-medical costs incurred in attending clinic-based cervical cancer screening, (b) investigating screening compliance and reasons for noncompliance, (c) determining women’s knowledge of human papillomavirus (HPV), its relationship to cervical cancer,…

Launches starts in CIS countries

Aprovix recently delivered 6,000 Qvintips to one of the former CIS states. This is the first step of three where the following step will increase the number of women participating to 10,000 already this fall. More news on this will follow. For more information, please contact us via info@aprovix.com

Aprovix launches new Cloud based screening solution

Aprovix have just released its latest version of QvinCloud that will help customers manage the entire process in their screening program. This will give operators easy access and maintenance of a complete screening program. For more info contact info@aprovix.com

Qvintip validated for high temperatures

Qvintip has together with our partner laboratory if choice been validated to withstand temperatures over 40 degrees in combination with high humidity, for more than two weeks without compromising the sample quality and end results. For more information please contact info@aprovix.com

Mideast healthcare providers show keen interest in Qvintip

Healthcare providers and public healthcare authorities participating in the Arab Health Exhibition in Dubai from 25 to 28 January showed keen interest in the Qvintip self-sampling HPV test for cervical cancer and all 14 high-risk HPV strains. An estimated 90 million women in the Middle East & North Africa (MENA) region are vulnerable to HPV…

Aprovix starts a roll-out in Pakistan!

We are happy to announce that we have secured a first pilot in Pakistan including 1,000 women for HPV testing to be escalated to 5,000 per month in the coming months.

Eurogin 2015

Aprovix will present at Eurogin 2015 in Seville, Spain on February 4-7th. Please see us at our booth 23!